← Back to Clinical Trials
Recruiting NCT07760402

NCT07760402 Effects Of Propofol And Sevoflurane On Plasma Mirna Levels İn Living Kidney Donors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07760402
Status Recruiting
Phase
Sponsor University of Gaziantep
Condition Kidney Transplant
Study Type INTERVENTIONAL
Enrollment 34 participants
Start Date 2026-05-01
Primary Completion 2026-10-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Sevofluranepropofol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 34 participants in total. It began in 2026-05-01 with a primary completion date of 2026-10-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Surgical interventions and associated tissue trauma induce a complex systemic inflammatory stress response characterized by the activation of neuroendocrine, metabolic, and immunological systems. Donor nephrectomy operations performed in living kidney donors are among the unique clinical models where these inflammatory cascades and cellular stress pathways are most intensely observed, due to major surgical trauma and unavoidable ischemia-reperfusion injury during organ clamping. Recent studies have demonstrated that microRNAs (miRNAs), which epigenetically regulate gene expression at the post-transcriptional level, serve as key determinants in perioperative medicine regarding immune response, resolution of inflammation, and cellular adaptation processes . Among our target molecules, miR-146a acts as a dominant, negative regulator (brake mechanism) of the innate immune response , while miR-155 plays an important role in the inflammatory response by triggering pro-inflammatory macrophage activation . Conversely, miR-21 displays an anti-apoptotic adaptation mechanism against tissue damage by directly targeting programmed cell death pathways . Propofol, an intravenous agent, and sevoflurane, a volatile anesthetic, are known to differentially impact microRNAs in circulating extracellular vesicles during major surgical interventions . The original value of this study lies in being the first randomized clinical trial in the literature to comprehensively examine the acute comparative effects of these two anesthesia techniques on perioperative inflammatory miRNA expression profiles in completely healthy living kidney donors. The objective is to comparatively evaluate the dynamic changes in plasma miR-146a, miR-155, and miR-21 levels under general anesthesia maintained with propofol or sevoflurane. Regarding the methodology, the research will be conducted on 34 voluntary living kidney donors aged 18-65 in the ASA I-II risk group, scheduled for elective donor nephrectomy at Gaziantep University Faculty of Medicine Şahinbey Training and Research Hospital, Department of Anesthesiology and Reanimation. Donors will be allocated into two equal groups (Group P: Propofol, n=17 and Group S: Sevoflurane, n=17) using a computer-assisted block randomization method, with anesthesia maintenance titrated to a Bispectral Index (BIS) of 40-60. Peripheral venous blood samples will be collected into K3-EDTA tubes at three different time points: before anesthesia induction (T0: basal), at the end of surgery (T1), and at the postoperative 24th hour (T2). In accordance with project management and data privacy principles, personal identity information will be masked, and each participant will be recorded in the system with a unique "File Number" (Dosya No). In the molecular phase conducted in coordination with the Department of Medical Genetics laboratory, total RNA isolation and cDNA synthesis will be performed from plasma samples separated under cold chain rules. Expression levels of target genes and the U6 snRNA internal control will be quantitatively analyzed in duplicate using Real-Time Quantitative PCR (RT-qPCR). Fold change ratios will be calculated using the method and analyzed with biostatistical methods including Shapiro-Wilk, Student's t-test, and Mann-Whitney U test. As for the widespread impact, the molecular findings to be obtained will elucidate the epigenetic reflections of general anesthesia applications on systemic inflammation and organ protection capacities for the first time. These results will lead to the development of the safest, evidence-based anesthesia protocols that will minimize the inflammatory load caused by surgical trauma at the cellular level in living kidney donors, increase donor comfort and postoperative recovery quality, and protect kidney graft quality against ischemic injury, providing a strong scientific foundation for international transplantation guidelines.

Eligibility Criteria

Inclusion Criteria: * Living kidney donors aged between 18 and 65 years. * Scheduled for an elective donor nephrectomy operation under general anesthesia. * American Society of Anesthesiologists (ASA) physical status I or II. * Body Mass Index (BMI) strictly less than 35 kg/m². * Provided written informed voluntary consent to participate in the study. Exclusion Criteria: * Known history or clinical diagnosis of malignancy or Diabetes Mellitus (DM). * Active or history of chronic systemic inflammatory or autoimmune diseases. * Chronic use of analgesics or documented history of substance abuse. * Known hypersensitivity or allergic reaction to any of the anesthetic agents used in the study (Sevoflurane or Propofol). * Diagnosed with dementia, severe cognitive impairment, or any significant psychiatric disorder.

Contact & Investigator

Central Contact

Elife SEVİLİR, Medical Doctor

✉ esev1234@gmail.com

📞 +905423794800

Principal Investigator

Rauf Gul, Professor Doctor

STUDY CHAIR

Gaziantep University Sahinbey Research and Application Hospital

Frequently Asked Questions

Who can join the NCT07760402 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Kidney Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07760402 currently recruiting?

Yes, NCT07760402 is actively recruiting participants. Contact the research team at esev1234@gmail.com for enrollment information.

Where is the NCT07760402 trial being conducted?

This trial is being conducted at Gaziantep, Turkey (Türkiye).

Who is sponsoring the NCT07760402 clinical trial?

NCT07760402 is sponsored by University of Gaziantep. The principal investigator is Rauf Gul, Professor Doctor at Gaziantep University Sahinbey Research and Application Hospital. The trial plans to enroll 34 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology